Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Fenaux

Showing results (311-320 of 320) with videos related to

Pageof 32
Sort By:
You have reached the last page of results.This site can display upto 320 results.
Blood Cancer Journal|August 1, 2015
An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategiesE Padron, G Garcia-Manero, M M Patnaik, et al.
Leukemia|March 18, 2005
Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogeneticsC Roche-Lestienne, S Lepers, V Soenen-Cornu, et al.
Leukemia|January 29, 2015
Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNetE Lengfelder, F Lo-Coco, L Ades, et al.
Annals of Hematology|January 30, 2013
High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFMC Kelaidi, O Beyne-Rauzy, T Braun, et al.
British Journal of Haematology|December 21, 2000
Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trialS De Botton, S Chevret, M Sanz, et al.
Leukemia & Lymphoma|October 12, 2020
Effects of azacitidine in 93 patients with <i>IDH1/2</i> mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter studyC Willekens, R Rahme, M Duchmann, et al.
Leukemia|February 1, 2012
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter studyU Germing, M Lauseker, B Hildebrandt, et al.
Leukemia|February 28, 2015
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)M G Della Porta, H Tuechler, L Malcovati, et al.
Leukemia|October 27, 2015
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletionA Toma, O Kosmider, S Chevret, et al.
The British Journal of Dermatology|October 11, 2021
Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patientsS Georgin-Lavialle, B Terrier, A F Guedon, et al.
Pageof 32

Showing results (311-320 of 320) with videos related to

Sort By:
Pageof 32
You have reached the last page of results.This site can display upto 320 results.
Blood Cancer Journal|August 1, 2015
An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategiesE Padron, G Garcia-Manero, M M Patnaik, et al.
Leukemia|March 18, 2005
Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogeneticsC Roche-Lestienne, S Lepers, V Soenen-Cornu, et al.
Leukemia|January 29, 2015
Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNetE Lengfelder, F Lo-Coco, L Ades, et al.
Annals of Hematology|January 30, 2013
High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFMC Kelaidi, O Beyne-Rauzy, T Braun, et al.
British Journal of Haematology|December 21, 2000
Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trialS De Botton, S Chevret, M Sanz, et al.
Leukemia & Lymphoma|October 12, 2020
Effects of azacitidine in 93 patients with <i>IDH1/2</i> mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter studyC Willekens, R Rahme, M Duchmann, et al.
Leukemia|February 1, 2012
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter studyU Germing, M Lauseker, B Hildebrandt, et al.
Leukemia|February 28, 2015
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)M G Della Porta, H Tuechler, L Malcovati, et al.
Leukemia|October 27, 2015
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletionA Toma, O Kosmider, S Chevret, et al.
The British Journal of Dermatology|October 11, 2021
Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patientsS Georgin-Lavialle, B Terrier, A F Guedon, et al.
Pageof 32